Michael Becka
Bayer (Germany)(DE)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Venous Thromboembolism Diagnosis and Management, Blood Coagulation and Thrombosis Mechanisms, Cardiac Arrhythmias and Treatments, Antiplatelet Therapy and Cardiovascular Diseases
Most-Cited Works
- → Serum markers detect the presence of liver fibrosis: A cohort study(2004)1,088 cited
- → Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor(2005)652 cited
- → Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects(2005)648 cited
- → Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban(2013)590 cited
- → Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor(2010)428 cited
- → Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects(2013)364 cited
- → Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects(2007)330 cited
- → Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects(2008)273 cited
- → Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects(2006)253 cited
- → The effect of food on the absorption and pharmacokinetics of rivaroxaban(2013)211 cited